Module

Join Stephane Chevaliez, PharmD, PhD; Paul J. Pockros, MD; and Stefan Zeuzem, MD, as they review and discuss key principles of HCV resistance with currently approved direct-acting antiviral agents, the latest resistance data on agents in development, and important considerations for potential future anti-HCV regimens. These expert faculty members also provide practical strategies for clinical challenges with the newly approved direct-acting agents through a case-based analysis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply strategies to reduce the development/expansion of resistance to direct-acting antiviral agents when managing patients receiving treatment with approved direct-acting antiviral agents in combination with peginterferon/ribavirin
  • Integrate key principles regarding antiviral resistance when evaluating data on the direct-acting antiviral agents currently in development
  • Evaluate potential future strategies for HCV treatment based on resistance considerations, including the barrier to resistance and patterns of cross-resistance among classes of direct-acting antiviral agents

Topics covered include:

  • Introduction to Drug Resistance in Hepatitis C Virus
  • Key Resistance Principles for Currently Approved Direct-Acting Antiviral Agents
  • Considerations for Retreatment of Previous Peginterferon/Ribavirin Null Responders and Potential Consequences of Protease Inhibitor Resistance
  • Genotype and Resistance Testing
  • Case 1: Previous Null Responder
  • Case 2: Stopping Rules
  • Case 3: Boceprevir Resistance–Associated Variant
  • Future Regimens
  • Future Protease Inhibitors
  • Nucleos(t)ide Polymerase Inhibitors
  • Nonnucleos(t)ide Polymerase Inhibitors
  • NS5A Inhibitors
  • Cyclophilin Inhibitors
  • Summary: Important Considerations to Avoid Resistance-Associated Variants
  • Appendix: Principles of HCV Resistance
 

Program Directors

  • Stefan Zeuzem
    MD

Faculty

  • Stéphane Chevaliez
    PharmD, PhD
    Paul J. Pockros
    MD

Credit Information

  • Release Date:
    October 25, 2011
  • Expiration Date:
    October 24, 2012
  • Physicians:
    maximum of 1.25 AMA PRA Category 1 Credits
  • How I Manage Patients With HCV After DAA Treatment Failure

    Jordan J. Feld MD, MPH - 1/19/2016    1 comment / Last Comment: 1/21/2016
    In the few HCV patients for whom DAA treatment fails, I consider a combination of 2 or more of the following: switching to a different DAA class, treating for longer, or adding ribavirin.
  • How I Use Resistance Testing to Guide Management of Patients With Chronic Hepatitis C

    Mark S. Sulkowski MD - 9/15/2015    11 comments / Last Comment: 12/18/2015
    Using a recent case patient, I outline my current approach to using HCV resistance testing to select therapy in patients who have previously received an HCV NS5A inhibitor.
  • My Evolving Strategy for Treating Patients With Genotype 3 HCV Infection

    Norah Terrault MD, MPH - 9/10/2015    8 comments / Last Comment: 12/19/2015
    Following the recent FDA approval of daclatasvir and the presentation of key data at the 2015 EASL meeting, our team has made several changes to our approach in managing patients with genotype 3 HCV infection.
  • Patients With Renal Disease: One of the Remaining Challenges in HCV Therapy

    Nancy Reau MD - 8/25/2015    27 comments / Last Comment: 1/22/2016
    A recent patient discussion highlighted important questions about how to approach HCV infection in renal disease.
  • Decompensated Cirrhosis: My Take on New Treatment Strategies Following AASLD 2015

    Ira M. Jacobson MD - 12/24/2015    2 comments / Last Comment: 1/4/2016
    Despite the variety of highly effective, highly tolerable regimens available for treating HCV, strategies for patients with decompensated liver disease remain challenging.